Japan Tobacco Inc. Financial Summary for Q3 FY2026 (IFRS) (Consolidated)

Overview of Results

For Q3 of FY2026 (consolidated), revenue was 2,991,382 million yen (YoY +13.6%) and operating income was 947,710 million yen (YoY +24.2%), showing steady growth. Meanwhile, profit attributable to owners of the parent for the period was 618,892 million yen, a significant decline YoY. The statements adopt a presentation that reflects the pharmaceutical business as a discontinued operation, and comparisons on a continuing-operations basis show growth. The full-year forecast is revenue of 3,903,000 million yen, operating income of 1,041,000 million yen, and profit of 662,000 million yen, with adjusted operating income on a constant currency basis estimated at 1,028,000 million yen.

Outlook and Impact for Investors

The company targets mid to high single digit average annual growth in adjusted operating income on a constant currency basis as a medium- to long-term objective. Taking into account the impact of comparative presentation due to the deconsolidation of the pharmaceutical business, the company will focus on strengthening earnings power of continuing operations. As of the end of September 2026, cash and cash equivalents were 8,873 million yen, and financial soundness has improved. Investors should note potential impacts such as installment payments related to settlement costs, but earnings presentation materials have been released; therefore, it is appropriate for investors to evaluate performance primarily on a continuing-operations basis.